KPV

Safety Risk (1.3/5.0). The safety profile is remarkably clean. KPV is an endogenous fragment of α-MSH, a naturally occurring hormone already present in human plasma. Per Getting 2006, KPV does not activate melanocortin receptors, eliminating the melanoma and pigmentation risks associated with full-length α-MSH and with other melanocortin peptides like melanotan. Near-zero adverse events reported in community use spanning a decade of gray-market availability. No serious safety signals in any source. The caveat is absence of long-term human data and the lack of regulated manufacturing, which makes vendor sourcing a real risk (third-party testing is non-optional). No intrinsic catastrophic floor trigger under v0.5 rules.

Side Effect Profile (1.3/5.0). Mild injection-site irritation on the subcutaneous route and occasional transient GI upset on the oral route. Both are infrequent and self-limiting. No headache, no rash, no mood signal, no fatigue above placebo background in community tracking. The topical route occasionally produces mild application-site redness that resolves on discontinuation. The intranasal route occasionally produces transient nasal irritation. Overall burden is substantially lower than most peptides (lower than BPC-157 for injection-site reactions, lower than thymosin alpha-1 for injection-site reactions, far lower than melanotan-II for side-effect profile).

Financial Cost (2.5/5.0). Gray-market sourcing ranges $40-100/month across oral, injectable, and intranasal routes at standard dosing. This is mid-range for peptide protocols, less expensive than BPC-157 or tesamorelin, more expensive than oral supplements like glutamine or colostrum. Compounding pharmacy access is uncertain during the pending FDA Category 1 reclassification process; if and when KPV moves to Cat 1, compounded access may open at potentially higher prices. Score per v0.5 accessible-channel rules: gray-market peptide vendors are the modal source for this population, not a premium branded channel.

Time/Effort Burden (2.0/5.0). Oral capsules are the simplest route and involve one daily dose, typically empty stomach AM. Subcutaneous injection adds syringe handling and storage complexity. Intranasal requires compounded spray. Topical cream requires compounding and consistent application. Sourcing adds moderate effort (verifying vendor, confirming third-party test certificates, handling reconstitution for lyophilized peptide). Dosing timing is not complex (short half-life but daily frequency is standard). Cycling (5-on/2-off or 4-8 week cycles) adds minor protocol complexity. Overall this is meaningfully higher effort than oral supplements but lower than most injectable peptide protocols.

Opportunity Cost (1.5/5.0). Complements rather than competes with most peptide and gut-healing protocols. Stacks cleanly with BPC-157 (most popular community pairing), glutamine, colostrum, low-dose naltrexone, and tributyrin. The main opportunity-cost consideration is not what KPV displaces but what else the user might try for a gut inflammation target with better evidence (low-dose naltrexone, AIP/carnivore dietary experiments, conventional IBD pharmacology). For users who have exhausted conventional options and are already in experimental-peptide territory, opportunity cost is minimal. For users who have not yet run a diagnostic workup or tried evidence-supported first-line interventions, opportunity cost is meaningful and KPV should not be the first move.

Dependency/Withdrawal (1.0/5.0). None demonstrated. No receptor downregulation mechanism is plausible given KPV does not activate melanocortin receptors. No HPA-axis involvement. No tolerance development in community reports across multi-month use. Per v0.5 dependency-vs-addiction framework, this sits at the mechanism-floor for substrate and non-receptor-agonist peptides: stopping produces no rebound, no craving, no withdrawal. The underlying inflammatory condition may re-emerge on discontinuation, but that is disease progression rather than drug dependency.

Reversibility (1.0/5.0). Fully reversible. The NF-kB-blockade mechanism is pharmacological and half-life-dependent; stopping KPV ends the blockade within hours to days. No adaptation has been demonstrated that would persist after discontinuation. No downstream epigenetic or tissue-level changes reported that would create irreversibility concern. Community experience reports that stopping the peptide returns users to their baseline inflammatory state over days to a couple of weeks, with no rebound inflammation above baseline. The absence of any sustained adaptation is a double-edged signal: safe to stop, but also implies chronic dosing for chronic conditions.